

# NUCLEIC ACID APTAMERS FOR DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS



**BIO071C**  
**September 2014**

Yojana Jeevane  
***Project Analyst***

ISBN: 1-56965-941-9



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVE	2
SCOPE OF THE REPORT	2
INTENDED AUDIENCE	3
INFORMATION AND METHODOLOGY SOURCES	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGY, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
INTRODUCTION	10
<i>FIGURE 1 SERVICE OFFERED UNDER APTAMER TECHNOLOGIES</i>	10
INCLINATION OF NANOPORE SENSORS TOWARD APTAMER TECHNOLOGY	10
APPLICATIONS OF NANOPORES IN DNA SEQUENCING	11
APPLICATION OF NANOPORES AS GENERAL BIOSENSORS	11
CMOS APPLICATION IN NANOPORE AND APTAMER TECHNOLOGIES	11
POTENTIAL OF FYNOMER TECHNOLOGY	12
TENASCIN-C APTAMERS	12
SMART APTAMERS	13
BLOOD PROTEIN DETECTION METHOD BASED UPON APTAMER	14
IMPROVED AND EFFICIENT POTENTIAL OF NUCLEIC ACID-BASED APTAMER LIBRARIES PATTERNED TO FORM IMPROVED SECONDARY STRUCTURE	15
NUCLEIC ACID-BASED APTAMERS AGAINST PROTEASES	15
NUCLEIC ACID-BASED APTAMER SELECTION FOR MONITORING GENE EXPRESSION USING BETA-GLUCURONIDASE	16
NUCLEIC ACID-BASED APTAMER THAT BINDS TO BISPHENOL A SPECIFICALLY	16
APTAMERS VS. ANTIBODIES	17
<i>TABLE 1 DIFFERENCE BETWEEN APTAMERS AND ANTIBODIES</i>	17
APTAMER CLASSIFICATION	18
NUCLEIC ACID APTAMERS	18
PEPTIDE APTAMERS	19
<i>FIGURE 2 APPLICATIONS OF PEPTIDE APTAMERS</i>	19
APTAMERS AS AFFINITY REAGENTS	20
APTAMERS AS MOLECULAR PROBES	20
APTAMERS IN CYTOMICS ANALYSIS	20
APTAMERS AS DIAGNOSTIC AND THERAPEUTIC AGENTS FOR LYMPHOMA	21
APTAMER SYNTHESIS AND MODIFICATIONS	21
APPLICATION IN DIAGNOSTICS AND THERAPEUTICS	22
ADVANTAGES OF APTAMERS	22

<b>TOPIC</b>	<b>PAGE NO.</b>
HIGHER STABILITY OF APTAMERS	23
PRODUCTION OF APTAMERS (MODIFICATION/SYNTHESIS)	23
IMMUNOGENICITY OF APTAMERS	24
VARIETY OF TARGETS	24
PORTER'S FIVE FORCES ANALYSIS OF THE NUCLEIC ACID APTAMER MARKET	24
<i>FIGURE 3 PORTER'S FIVE FORCE MODEL OF THE NUCLEIC ACID APTAMER TECHNOLOGY MARKET</i>	24
BARGAINING POWER OF SUPPLIERS-LOW	25
BARGAINING POWER OF BUYERS-HIGH	25
INTENSITY OF COMPETITION-HIGH	26
THREAT OF SUBSTITUTE PRODUCTS-HIGH	26
THREAT OF NEW ENTRANTS-HIGH	26
GOVERNMENT REGULATIONS AND LEGISLATION	27
REGULATORY CHALLENGES IN THE UNITED STATES AND EUROPE	27
<i>TABLE 2 ICH* GUIDELINES APPLICABLE TO THERAPEUTICS BASED UPON SYNTHETIC OLIGONUCLEOTIDES</i>	28
Guidelines for Reimbursement	28
Documentation Requirements	30
<i>TABLE 3 MACUGEN (PEGAPTANIB SODIUM) CODES FOR REIMBURSEMENT</i>	30
<i>FIGURE 4 HISTORICAL MILESTONE FOR MACUGEN (PEGAPTANIB SODIUM) REIMBURSEMENT PROGRAM</i>	30
CLINICAL TRIALS COMPLETED	31
<i>TABLE 4 CLINICAL TRIALS OF APTAMER RESEARCH (COMPLETED)</i>	32
CLINICAL TRIALS TERMINATED	33
<i>TABLE 5 CLINICAL TRIALS OF APTAMER RESEARCH (TERMINATED)</i>	34
CLINICAL TRIALS IN PROGRESS	34
<i>TABLE 6 CLINICAL TRIALS OF APTAMER RESEARCH (IN PROGRESS)</i>	35
MARKET DYNAMICS	36
DRIVERS	36
Scope of Applications for Nucleic Acid-based Aptamer Technology	36
Therapeutics	36
Diagnostics	37
Research	37
Advantages of Aptamers Make Them a Novel Approach for Different Applications	38
Aptamer Significance over Antibodies	38
Increasing Number/Frequency of Clinical Trials	39
RESTRAINTS	40
OPPORTUNITIES	40
CHAPTER 4 NUCLEIC ACID APTAMERS MARKET BY TECHNOLOGIES	42
<i>TABLE 7 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)</i>	42
ENABLING TECHNOLOGY	42
<i>TABLE 8 GLOBAL MARKET FOR ENABLING TECHNOLOGY BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	42
SELEX TECHNOLOGY	43
<i>TABLE 9 GLOBAL MARKET FOR SELEX TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	43

<b>TOPIC</b>	<b>PAGE NO.</b>
General SELEX Technology	43
<i>FIGURE 5 PROCESS OF GENERAL SELEX TECHNOLOGY</i>	44
SELEX Process Based upon Nitrocellulose Membrane Filtration	44
SELEX Process Based upon Magnetic Bead and Affinity Chromatography	45
<i>FIGURE 6 SELEX PROCESS BASED UPON MAGNETIC BEAD AND AFFINITY CHROMATOGRAPHY</i>	45
SELEX Based upon Capillary Electrophoresis	45
<i>FIGURE 7 FUNDAMENTAL PRINCIPLE OF CAPILLARY ELECTROPHORESIS</i>	45
SELEX Based upon Microfluidics	46
MODIFIED OLIGONUCLEOTIDES	46
<i>TABLE 10 GLOBAL MARKET FOR MODIFIED OLIGONUCLEOTIDES TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	47
OLIGONUCLEOTIDES SYNTHESIS	47
<i>TABLE 11 GLOBAL MARKET FOR OLIGONUCLEOTIDES SYNTHESIS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	47
NEXT-GENERATION SEQUENCING	48
<i>TABLE 12 GLOBAL MARKET FOR NEXT-GENERATION SEQUENCING TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	48
NANOPARTICLES AND QUANTUM DOT LABELS	48
<i>TABLE 13 GLOBAL MARKET FOR NANOPARTICLES AND QUANTUM DOT LABELS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	49
SURFACE PLASMON RESONANCE AND BIOLAYER INTERFEROMETRY	49
<i>TABLE 14 GLOBAL MARKET FOR SURFACE PLASMON RESONANCE AND BIOLAYER INTERFEROMETRY TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	50
BIOINFORMATICS	50
<i>TABLE 15 GLOBAL MARKET FOR BIOINFORMATICS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	50
APTAMERS AS DIAGNOSTIC SENSORS	51
<i>TABLE 16 GLOBAL MARKET FOR DIAGNOSTIC SENSORS TECHNOLOGY BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 17 GLOBAL MARKET FOR DIAGNOSTIC SENSORS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	51
SENSOR PLATFORM TECHNOLOGIES	52
<i>TABLE 18 GLOBAL MARKET FOR SENSOR PLATFORM TECHNOLOGIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	52
SELF-REPORTING SENSORS	53
<i>TABLE 19 GLOBAL MARKET FOR SELF-REPORTING SENSORS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	53
TRENDS IN APTAMERS AS DIAGNOSTICS	53
APTAMERS AS THERAPEUTICS	54
APTAMERS AND INFECTIOUS DISEASE	54
APTAMERS AS TARGETING AGENTS	54
APTAMER MODIFICATIONS	55
CAPTAMERS	55
WHOLE CELL SELEX	55
VEGF APTAMERS	56
CHAPTER 5 NUCLEIC ACID APTAMERS MARKET BY APPLICATION	58

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 20 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	58
<i>FIGURE 8 APPLICATIONS OF NUCLEIC ACID APTAMERS</i>	58
APPLICATION OF APTAMERS AS DIAGNOSTICS	59
<i>TABLE 21 GLOBAL NUCLEIC ACID APTAMERS DIAGNOSTIC APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	59
ENVIRONMENTAL MONITORING, FOOD AND WATER SAFETY	59
Aptasensors in Opposition to Small Molecules	61
Aptasensors against Antibiotics	61
Chloramphenicol (Cam)	61
Tetracycline	61
Aminoglycoside	62
Aptasensors against Toxins	62
Aptasensors against Contaminants Present in Food Packaging	63
Aptasensors against Heavy Metals	63
Aptasensors against Pesticides	63
Aptasensors in Opposition to Pathogens	64
Viruses	64
Bacteria	64
HUMAN CLINICAL DIAGNOSTIC ASSAYS	65
APTAMER-BASED DIAGNOSTICS FOR INFLUENZA VIRUSES IN HUMANS	65
APTAMER-BASED CLINICAL BIOMARKER ASSAYS	65
APTAMER-BASED COLORIMETRIC ASSAY FOR DETECTING CANCER CELLS	66
APPLICATION OF APTAMERS IN VETERINARY DIAGNOSTICS	66
APPLICATION OF APTAMERS AS THERAPEUTICS	67
<i>TABLE 22 APTAMERS AS TARGETS OF THERAPEUTIC INTEREST</i>	67
<i>TABLE 23 GLOBAL NUCLEIC ACID APTAMERS THERAPEUTIC APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	69
DRUG DELIVERY VEHICLES IN CANCER	69
NANOPARTICLE-BASED DRUG DELIVERY VEHICLES	70
PROSTATE CANCER TARGETING APTAMER	70
LEUKEMIA TARGETING APTAMER	71
NUCLEOLIN TARGETING APTAMER	71
OTHER TARGETING APTAMERS	71
DNA APTAMER-MICELLE-BASED DRUG DELIVERY VEHICLE	71
APTAMER-LIPOSOME BASED DRUG DELIVERY VEHICLE	72
DNA-APTAMER-BASED CARGOES AS DRUG DELIVERY VEHICLES IN CANCER	72
<i>TABLE 24 APTAMERS WITH THEIR CARGOES AND INTERNALIZED TARGETS ON CANCER CELLS</i>	72
Endocytic Pathway Driven by Aptamer-cargoes	74
MODIFIERS OF SURGICAL IMPLANTS	74
BIOSEPARATION PROCESSES	74
<i>TABLE 25 APTAMER-BASED SEPARATION USED IN AFFINITY CHROMATOGRAPHY</i>	75
APPLICATION OF APTAMERS IN RESEARCH	75
<i>TABLE 26 GLOBAL NUCLEIC ACID APTAMERS RESEARCH APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	76
FLOW CYTOMETRY	76
MASS SPECTROMETRY	77

<b>TOPIC</b>	<b>PAGE NO.</b>
WESTERN BLOTTING	77
REAGENTS AND ASSAYS	77
APPLICATION OF APTAMERS AS BIOSENSORS	78
<i>TABLE 27 GLOBAL NUCLEIC ACID APTAMERS BIOSENSORAPPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	79
APTAMERS FOR SMALL MOLECULE TARGETS REGARDING FOOD SAFETY	80
<i>TABLE 28 APTAMERS AND APTAMERS-BASED BIOSENSOR FOR TARGETS CONTAINING SMALL MOLECULES</i>	80
Antibiotics	81
Mycotoxins	82
Heavy Metals	82
APTAMERS FOR FOOD PATHOGENS RELATED TO SAFETY	82
<i>TABLE 29 APTAMER-BASED BIOSENSORS FOR MACROMOLECULAR TARGETS AND PATHOGENS</i>	83
Bacteria	84
Viruses	84
Other Macromolecular Targets	84
APPLICATION IN BIOMARKERS DISCOVERY	85
<i>TABLE 30 GLOBAL NUCLEIC ACID APTAMER BIOMARKERS DISCOVERY APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	85
CHAPTER 6 NUCLEIC ACID APTAMER MARKET BY REGION	87
<i>TABLE 31 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
NORTH AMERICA	87
<i>TABLE 32 NORTH AMERICA MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	88
EUROPE	88
<i>TABLE 33 EUROPE MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	89
ASIA-PACIFIC	89
<i>TABLE 34 ASIA-PACIFIC MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	90
ROW	90
<i>TABLE 35 ROW MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	91
CHAPTER 7 COMPETITIVE LANDSCAPE	93
<i>FIGURE 9 KEY COMPETITIVE STRATEGIES BY TYPE OF DEVELOPMENT, 2010-2014 (PERCENT)</i>	93
CLINICAL TRIALS	94
<i>FIGURE 10 CLINICAL TRIALS BY COMPANIES, 2010-2014 (NUMBER)</i>	95
<i>TABLE 36 CLINICAL TRIALS BETWEEN 2010 AND 2014</i>	96
COLLABORATION	97
<i>FIGURE 11 COLLABORATION STRATEGY BY APPLICATION, 2010-2014 (NUMBER)</i>	97
<i>TABLE 37 COLLABORATIONS BETWEEN 2010 AND 2014</i>	98
AGREEMENTS	99
<i>FIGURE 12 AGREEMENT STRATEGY BY COMPANIES, 2010-2014 (%)</i>	100
<i>TABLE 38 AGREEMENTS BETWEEN 2010 AND 2014</i>	100

TOPIC	PAGE NO.
RESEARCH & DEVELOPMENT	101
<i>FIGURE 13 RESEARCH AND DEVELOPMENT STRATEGY BY COMPANIES, 2010-2014 (NUMBER)</i>	102
<i>TABLE 39 RESEARCH AND DEVELOPMENT BETWEEN 2010 AND 2014</i>	102
CHAPTER 8 PATENT ANALYSIS	105
<i>FIGURE 14 PATENTS REGISTERED/APPROVED BY REGION, 2011-2014 (PERCENT)</i>	105
U.S. PATENT ANALYSIS BY MARKET PARTICIPANT	106
<i>FIGURE 15 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	106
EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT	107
<i>FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, -2011-2014 (NUMBER/%)</i>	107
JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT	108
<i>FIGURE 17 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)</i>	108
CHAPTER 9 COMPANY PROFILES	111
ALIMERA SCIENCES	111
<i>TABLE 40 ALIMERA SCIENCES FINANCIALS, 2012 AND 2013 (\$ MILLIONS)</i>	111
ALNYLAM PHARMACEUTICALS	111
<i>TABLE 41 ALNYLAM PHARMACEUTICALS FINANCIALS, 2011 AND 2012 (\$ MILLIONS)</i>	112
AM BIOTECHNOLOGIES LLC	112
APTAMER PRODUCT OVERVIEW	112
APTAGEN LLC	113
APTAMATRIX INC	113
APTAMER SCIENCES INC.	113
APTAMER PRODUCT OVERVIEW	114
<i>TABLE 42 RECENT DEVELOPMENTS OF APTAMER SCIENCES INC.</i>	114
APTARES AG	114
APTASOL (APTAMER SOLUTIONS) LTD	115
APTAMER PRODUCT AND SERVICES OVERVIEW	115
<i>TABLE 43 RECENT DEVELOPMENTS OF APTASOL (APTAMER SOLUTIONS) LTD</i>	116
APTUS BIOTECH SL	116
BASE PAIR BIOTECHNOLOGIES INC.	116
APTAMER PRODUCT OVERVIEW	117
<i>TABLE 44 RECENT DEVELOPMENTS OF BASE PAIR BIOTECHNOLOGIES INC.</i>	117
ISIS PHARMACEUTICALS	118
LUCERNA INC	118
MITSUI & CO. (U.S.A.) INC..	118
<i>TABLE 45 MITSUI &amp; CO. (U.S.A.) INC. FINANCIALS, 2013 AND 2014 (\$ MILLIONS)</i>	119
NEOVENTURES BIOTECHNOLOGY INC	119
APTAMERS PRODUCT AND APPLICATIONS OVERVIEW	119
<i>TABLE 46 RECENT DEVELOPMENTS OF NEOVENTURES BIOTECHNOLOGY INC</i>	120
NOXXON PHARMA AG	120
APTAMER PRODUCT OVERVIEW	120
<i>TABLE 47 RECENT DEVELOPMENTS OF NOXXON</i>	121
OPHTHOTECH CORP.	121
APTAMER PRODUCT OVERVIEW	122
<i>TABLE 48 RECENT DEVELOPMENTS OF OPHOTOTECH CORP.</i>	122

<b>TOPIC</b>	<b>PAGE NO.</b>
OTC BIOTECH	122
PFIZER	123
<i>TABLE 49 PFIZER FINANCIALS, 201-2013 (\$ MILLIONS)</i>	123
QUEST DIAGNOSTICS	123
<i>TABLE 50 QUEST DIAGNOSTICS FINANCIALS, 2011-2013 (\$ MILLIONS)</i>	124
REGADO BIOSCIENCES	124
<i>TABLE 51 RECENT DEVELOPMENTS OF REGADO BIOSCIENCES</i>	124
RINA GMBH	125
APTAMER PRODUCT OVERVIEW	125
<i>TABLE 52 RECENT DEVELOPMENTS OF RINA GMBH</i>	126
SOMALOGIC INC.	126
APTAMER PRODUCT OVERVIEW	126
<i>TABLE 53 RECENT DEVELOPMENTS OF SOMALOGIC INC.</i>	127
SUMITOMO BAKELITE CO. LTD.	127
<i>TABLE 54 SUMITOMO BAKELITE CO LTD FINANCIALS, 2011-2014 (\$ MILLIONS)</i>	128
CHAPTER 10 APPENDIX	130
LIST OF PATENTS: NORTH AMERICA	130
<i>TABLE 55 LIST OF PATENTS: NORTH AMERICA</i>	130
LIST OF PATENTS: EUROPE	131
<i>TABLE 56 LIST OF PATENTS: EUROPE</i>	131
LIST OF PATENTS: JAPAN	132
<i>TABLE 57 LIST OF PATENTS: JAPAN</i>	132



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 DIFFERENCE BETWEEN APTAMERS AND ANTIBODIES	17
TABLE 2 ICH* GUIDELINES APPLICABLE TO THERAPEUTICS BASED UPON SYNTHETIC OLIGONUCLEOTIDES	28
TABLE 3 MACUGEN (PEGAPTANIB SODIUM) CODES FOR REIMBURSEMENT	30
TABLE 4 CLINICAL TRIALS OF APTAMER RESEARCH (COMPLETED)	32
TABLE 5 CLINICAL TRIALS OF APTAMER RESEARCH (TERMINATED)	34
TABLE 6 CLINICAL TRIALS OF APTAMER RESEARCH (IN PROGRESS)	35
TABLE 7 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)	42
TABLE 8 GLOBAL MARKET FOR ENABLING TECHNOLOGY BY TYPE, THROUGH 2019 (\$ MILLIONS)	42
TABLE 9 GLOBAL MARKET FOR SELEX TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	43
TABLE 10 GLOBAL MARKET FOR MODIFIED OLIGONUCLEOTIDES TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	47
TABLE 11 GLOBAL MARKET FOR OLIGONUCLEOTIDES SYNTHESIS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	47
TABLE 12 GLOBAL MARKET FOR NEXT-GENERATION SEQUENCING TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	48
TABLE 13 GLOBAL MARKET FOR NANOPARTICLES AND QUANTUM DOT LABELS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	49
TABLE 14 GLOBAL MARKET FOR SURFACE PLASMON RESONANCE AND BIOLAYER INTERFEROMETRY TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	50
TABLE 15 GLOBAL MARKET FOR BIOINFORMATICS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	50
TABLE 16 GLOBAL MARKET FOR DIAGNOSTIC SENSORS TECHNOLOGY BY TYPE, THROUGH 2019 (\$ MILLIONS)	51
TABLE 17 GLOBAL MARKET FOR DIAGNOSTIC SENSORS TECHNOLOGY BY REGION, THROUGH 2019 (\$ MILLIONS)	51
TABLE 18 GLOBAL MARKET FOR SENSOR PLATFORM TECHNOLOGIES BY REGION, THROUGH 2019 (\$ MILLIONS)	52
TABLE 19 GLOBAL MARKET FOR SELF-REPORTING SENSORS BY REGION, THROUGH 2019 (\$ MILLIONS)	53
TABLE 20 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	58
TABLE 21 GLOBAL NUCLEIC ACID APTAMERS DIAGNOSTIC APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	59
TABLE 22 APTAMERS AS TARGETS OF THERAPEUTIC INTEREST	67
TABLE 23 GLOBAL NUCLEIC ACID APTAMERS THERAPEUTIC APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 24 APTAMERS WITH THEIR CARGOES AND INTERNALIZED TARGETS ON CANCER CELLS	72
TABLE 25 APTAMER-BASED SEPARATION USED IN AFFINITY CHROMATOGRAPHY	75
TABLE 26 GLOBAL NUCLEIC ACID APTAMERS RESEARCH APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	76
TABLE 27 GLOBAL NUCLEIC ACID APTAMERS BIOSENSORAPPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	79
TABLE 28 APTAMERS AND APTAMERS-BASED BIOSENSOR FOR TARGETS CONTAINING SMALL MOLECULES	80

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 29 APTAMER-BASED BIOSENSORS FOR MACROMOLECULAR TARGETS AND PATHOGENS	83
TABLE 30 GLOBAL NUCLEIC ACID APTAMER BIOMARKERS DISCOVERY APPLICATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	85
TABLE 31 GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 32 NORTH AMERICA MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	88
TABLE 33 EUROPE MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	89
TABLE 34 ASIA-PACIFIC MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	90
TABLE 35 ROW MARKET FOR NUCLEIC ACID APTAMERS BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	91
TABLE 36 CLINICAL TRIALS BETWEEN 2010 AND 2014	96
TABLE 37 COLLABORATIONS BETWEEN 2010 AND 2014	98
TABLE 38 AGREEMENTS BETWEEN 2010 AND 2014	100
TABLE 39 RESEARCH AND DEVELOPMENT BETWEEN 2010 AND 2014	102
TABLE 40 ALIMERA SCIENCES FINANCIALS, 2012 AND 2013 (\$ MILLIONS)	111
TABLE 41 ALNYLAM PHARMACEUTICALS FINANCIALS, 2011 AND 2012 (\$ MILLIONS)	112
TABLE 42 RECENT DEVELOPMENTS OF APTAMER SCIENCES INC.	114
TABLE 43 RECENT DEVELOPMENTS OF APTASOL (APTAMER SOLUTIONS) LTD	116
TABLE 44 RECENT DEVELOPMENTS OF BASE PAIR BIOTECHNOLOGIES INC.	117
TABLE 45 MITSUI & CO. (U.S.A.) INC. FINANCIALS, 2013 AND 2014 (\$ MILLIONS)	119
TABLE 46 RECENT DEVELOPMENTS OF NEOVENTURES BIOTECHNOLOGY INC	120
TABLE 47 RECENT DEVELOPMENTS OF NOXXON	121
TABLE 48 RECENT DEVELOPMENTS OF OPHTHOTECH CORP.	122
TABLE 49 PFIZER FINANCIALS, 201-2013 (\$ MILLIONS)	123
TABLE 50 QUEST DIAGNOSTICS FINANCIALS, 2011-2013 (\$ MILLIONS)	124
TABLE 51 RECENT DEVELOPMENTS OF REGADO BIOSCIENCES	124
TABLE 52 RECENT DEVELOPMENTS OF RINA GMBH	126
TABLE 53 RECENT DEVELOPMENTS OF SOMALOGIC INC.	127
TABLE 54 SUMITOMO BAKELITE CO LTD FINANCIALS, 2011-2014 (\$ MILLIONS)	128
TABLE 55 LIST OF PATENTS: NORTH AMERICA	130
TABLE 56 LIST OF PATENTS: EUROPE	131
TABLE 57 LIST OF PATENTS: JAPAN	132

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR NUCLEIC ACID APTAMERS BY TECHNOLOGY, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 SERVICE OFFERED UNDER APTAMER TECHNOLOGIES	10
FIGURE 2 APPLICATIONS OF PEPTIDE APTAMERS	19
FIGURE 3 PORTER'S FIVE FORCE MODEL OF THE NUCLEIC ACID APTAMER TECHNOLOGY MARKET	24
FIGURE 4 HISTORICAL MILESTONE FOR MACUGEN (PEGAPTANIB SODIUM) REIMBURSEMENT PROGRAM	30
FIGURE 5 PROCESS OF GENERAL SELEX TECHNOLOGY	44
FIGURE 6 SELEX PROCESS BASED UPON MAGNETIC BEAD AND AFFINITY CHROMATOGRAPHY	45
FIGURE 7 FUNDAMENTAL PRINCIPLE OF CAPILLARY ELECTROPHORESIS	45
FIGURE 8 APPLICATIONS OF NUCLEIC ACID APTAMERS	58
FIGURE 9 KEY COMPETITIVE STRATEGIES BY TYPE OF DEVELOPMENT, 2010-2014 (PERCENT)	93
FIGURE 10 CLINICAL TRIALS BY COMPANIES, 2010-2014 (NUMBER)	95
FIGURE 11 COLLABORATION STRATEGY BY APPLICATION, 2010-2014 (NUMBER)	97
FIGURE 12 AGREEMENT STRATEGY BY COMPANIES, 2010-2014 (%)	100
FIGURE 13 RESEARCH AND DEVELOPMENT STRATEGY BY COMPANIES, 2010-2014 (NUMBER)	102
FIGURE 14 PATENTS REGISTERED/APPROVED BY REGION, 2011-2014 (PERCENT)	105
FIGURE 15 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	106
FIGURE 16 EUROPE PATENT ANALYSIS BY MARKET PARTICIPANT, -2011-2014 (NUMBER/%)	107
FIGURE 17 JAPAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)	108